Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 33 for “"rituximab"”.
-
Probing the sensitivity of autoantibody production to B cell depletion by Rituximab
Rituximab, a monoclonal antibody directed against the human CD20 antigen, causes profound depletion of all B cells. When used in patients with autoimmune disease, IgG autoantibody titres often fall whilst serum IgG anti-tetanus toxoid antibody titres are unaffected. Antibodies of both these …
-
Review of Diffuse large B cell lymphoma, pharmacological aspects of treatment and comparison of outcome between Pre-,Post Rituximab era
… due to gene expression variability. Nowadays Rituximab is the gold standard treatment of NHL which is targeting monoclonal antibody of CD20 and it also shows good prognosis to DLBCL. Rituximab containing chemotherapy regimen like R-CHOP shows relatively good response to DLBCL compare to …
-
Comparación farmacoeconómica (costo – utilidad / beneficio / efectividad) del Rituximab, con el tratamiento convencional para pacientes con Linfoma No Hodgkins
… con quimioterapia (CHOP) y el tratamiento con Rituximab + CHOP Objetivo: Evaluar comparativamente el tratamiento con quimioterapia y el Rituximab en cuanto a costo beneficio / utilidad /efectividad y el efecto de ambas terapias sobre la calidad de vida y carga de enfermedad, desde la …
-
Adoption of Innovation: Impact of Rituximab (Rituxan®) Faster Infusion on Oncology Nurses' Perceptions, Practice, and Resource Utilization
… (FDA) approval of a 90-minute infusion of rituximab (Rituxan) starting at Cycle 2 for patients with non-Hodgkin’s lymphoma who did not experience a Grade 3 or 4 infusion-related adverse event during Cycle 1. The 90-minute rituximab faster infusion will result in a significant change in how …
-
Papel del anticuerpo monoclonal anti-CD20 (rituximab) en el tratamiento del lupus eritematoso sistémico refractario al uso de inmunsupresores
… de la siguiente hipótesis de trabajo: El uso de Rituximab en pacientes con LES refractarios a inmunosupresores provoca una mejora tanto de los marcadores clínicos, como analíticos, así como, una reducción de los tratamientos coadyu
-
Estudio Farmacogenético de la Respuesta al Anticuerpo Monoclonal Anti-CD20 (Rituximab) en el Tratamiento de Pacientes con Linfoma Folicular.
… a la terapia convencional. La incorporación del rituximab, un anticuerpo monoclonal quimérico anti-CD20, como inmunoterapia en el tratamiento del linfoma folicular se ha convertido en una terapia esencial, mejorando de forma significativa la supervivencia y presentando un perfil de toxicidad …
-
B cell therapy in ANCA-associated vasculitis
… the efficacy of B cell depletion therapy with rituximab as both an induction and maintenance agent. Rituximab, the only licenced therapy for AAV, is associated with a remission failure rate of 10-30%, and for those who achieve remission, repeated doses are needed to prevent relapses, increasing …
-
Understanding the Mechanism of Action of Rituximab in the Reversal of Multidrug Resistance in a Non-Hodgkins Lymphoma Cell Line
… rafts). By redistributing CD20 into rafts, Rituximab(tm) (RTX) modified their stability and organization. P-glycoprotein (P-gp) is the constituent protein of MDR tumor cells and is responsible for pumping chemotherapeutic agents out of cells. Because ~40% of P-gp is contained in lipid rafts, …
-
Monoclonal Antibody Therapy: The Development of a Liquid Chromatography Tandem Mass Spectrometry Method to Measure Rituximab Concentrations in Human Plasma
… the pursuit of tumour-targeted therapies. Rituximab (RTX) is one such mAb which has been of substantial interest in recent years as a therapy. The aim of this research project is to develop and optimise the extraction and quantification of RTX in human plasma using appropriate sample …
-
PHARMACOLOGICAL MODULATION OF THE ADAPTIVE IMMUNE SYSTEM IN ISCHAEMIC HEART DISEASE
… myocardial injury and improved cardiac function. Rituximab is a monoclonal antibody targeted against human B cells and has been used in the treatment of certain autoimmune diseases and cancers. However, its use in cardiovascular disease is untested and is currently contraindicated. Therefore, a …
-
The synergistic interaction between CD20 monoclonal antibodies and Histone Deacetylase inhibitors in B cell Non Hodgkin’s Lymphoma
… The anti-CD20 monoclonal antibody, Rituximab, has resulted in<br/>dramatic improvements in survival for patients with B cell Non Hodgkin’s<br/>lymphoma. Histone deacetylase inhibitors are a novel class of anti cancer<br/>agents targeting epigenetic regulation.<br/><br/>This thesis …
-
Targeted therapies in mantle cell lymphoma
… to B cell clonal expansion and influences Rituximab-mediated cell death in MCL models. Rituximab is a chimeric monoclonal antibody targeted against B cells and both Rituximab-sensitive and insensitive MCL models were defined. An abnormally high expression of bcl-2, bcl-x L, mcl-1, …
-
Hochdosis-Chemotherapie gefolgt von einer myeloablativen Hochdosis-Radioimmuntherapie (HD-RAIT) mit Iod-131-Rituximab und peripherer Stammzelltransplantation (SCTx) bei primär refraktären und rezidivierten Non-Hodgkin-Lymphomen
… von einer myeloablativen HD-RAIT mit Iod-131-Rituximab und SCTx. Methoden: In die Studie eingeschlossen wurden 19 Patienten mit rezidivierten oder refraktären Non-Hodgkin-Lymphomen. Da 4 Patienten nach Einschluss in die Studie die Therapiekriterien nicht erfüllten, wurden insgesamt 15 …
-
Investigating heterogeneity and mechanisms of resistance in paediatric B-cell non-Hodgkin lymphoma
… chemotherapy, followed by the addition of Rituximab, resulting in a survival rate exceeding 90%. Despite this, those patients who acquire resistance to chemotherapy and/or Rituximab have a dismal prognosis with few salvage therapy options. The aim of this thesis was to identify cell …
-
Lineáris poliakrilamiddal borított kapillárisok előállítása fehérjék kapilláris zónaelektroforetikus elemzéséhez
… tulajdonságokkal bíró fehérje keverékoldatot (rituximab, hemoglobin, inzulin) használtunk, a CZE elválasztásához háttérelektrolitként 50 mM HCOOH (2,6 pH) alkalmaztunk. Az LPA-val bevont kapillárisok kiválóan alkalmasak fehérjék meghatározásához, a fali adszorpció kiküszöbölhető, szelektívebb, …
-
Splenectomy for immune thrombocytopenia : our 11-year experience
… treat ITP, including immune-suppressants such as rituximab and the new thrombopoetin-receptor agonists. This has brought into question the role of surgery for the treatment of ITP, and the need to compare the response and complication rates of splenectomy to these newer agents. Historic studies …
-
Elucidating Targetable Genetic Vulnerabilities in Relapsed/Refractory Diffuse Large B-cell Lymphoma
… with cyclophosphamide, doxorubicin, prednisone, rituximab, and vincristine (R-CHOP); however, the relapse rate remains high, underscoring the need for improved diagnostic and therapeutic methods. In this comprehensive analysis, we investigated the genetic substructure of DLBCL in both newly …
-
Descripción de pacientes con miopatías inflamatorias en un hospital de cuarto nivel, centro de referencia de enfermedades autoinmunes y reumáticas e n Bogotá, Colombia. 2022-2024
… azatioprina, 16.2% con metotrexato y 4.6% con Rituximab.
Page 1 of 2